The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed
Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease
Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors
Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes
Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China
Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy
Positive results are reported from the FZOCUS-1 and ICON8B studies
Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain
As it emerges from some studies presented across different cancers, toxicity remains a major challenge
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.